Richter Reaffirms Buy Rating on Amgen Amid Strong Analyst Track Record

Goldman Sachs analyst Salveen Richter has reaffirmed her buy rating for Amgen (AMGN.US), maintaining a target price of $450. This recommendation is based on the analyst's past performance, which shows a success rate of 50.4% and an average return of 12.3% over the past year.

The data provided by TipRanks, an independent third-party analysis platform, supports Richter's rating. According to TipRanks, the analyst has a strong track record, with a 5-star ranking out of a possible 5.

It is worth noting that TipRanks' virtual portfolio based on Richter's recommendations has earned a positive return over the past year. The platform uses a combination of data and analytics to evaluate financial analysts and provide insights into their performance.